Serum Levels of Soluble ICAM-1 in Lung Cancer Patients
Author Information
Author(s): A Grothey, P Heistermann, S Philippou, R Voigtmann
Primary Institution: Ruhr-University of Bochum
Hypothesis
The study investigates the correlation between serum levels of soluble intercellular adhesion molecule-1 (sICAM-1) and tumor stage in patients with non-small-cell lung cancer (NSCLC).
Conclusion
Serum levels of sICAM-1 are associated with tumor burden and histological expression of ICAM-1 in patients with NSCLC.
Supporting Evidence
- Patients with NSCLC had significantly higher serum levels of sICAM-1 compared to healthy non-smokers.
- Metastatic disease was associated with higher sICAM-1 levels than localized tumors.
- Histological expression of ICAM-1 was positively correlated with serum sICAM-1 levels.
Takeaway
This study found that patients with lung cancer have higher levels of a specific protein in their blood compared to healthy people, and those with more advanced cancer have even higher levels.
Methodology
Serum levels of sICAM-1 were analyzed using a sandwich ELISA technique on blood samples from patients with NSCLC and a control group of healthy individuals.
Potential Biases
Potential bias due to the small number of non-smokers in the patient group and the reliance on serum levels as a marker without direct correlation to clinical outcomes.
Limitations
The study did not establish a direct causal relationship between sICAM-1 levels and prognosis, and the sample size for sequential analysis was small.
Participant Demographics
51 patients (46 male, 5 female; age 38-81 years, median 64 years) with NSCLC and 40 healthy individuals (20 smokers, 20 non-smokers).
Statistical Information
P-Value
0.00001
Confidence Interval
95% CI for metastatic NSCLC: 387.3-540.3; for localized NSCLC: 278.8-356.7
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website